Glenmark Pharmaceuticals Europe Ltd. has unveiled a generic version of Seretide Accuhaler in Denmark. Glenmark on Wednesday said this was the company’s first inhaled respiratory product introduction in Europe. It is the first generic firm to get regulatory approval for substitution in Denmark for the generic version of GlaxoSmithKline’s Seretide Accuhaler, according to a statement from Glenmark.Glenmark had entered into a strategic development and licensing agreement with Celon Pharma S.A. to develop and market the generic version – Fluticasone/Salmeterol dry powder inhaler in 15 European countries.
The Fluticasone/Salmeterol dry powder inhaler is a combination product for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Glenmark had already received National Marketing Authorisations for the product in Sweden, Finland, Norway and Iceland.
“Denmark is the first country in Europe where Glenmark has launched its generic Fluticasone/Salmeterol Dry powder Inhaler (DPI) and we plan to commercialize this product across the Nordics in the near future,” said Achin Gupta, Executive Vice President and Business Head of Europe and Latin America, Glenmark Pharmaceuticals Ltd.
The release, quoting IQVIA data, said Fluticasone/Salmeterol DPI had sales of $ 864 million in Europe during the 12 month ended September 2017.
